Study: NCT04735822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence ABFCED
Description: Oral suspension belumosudil 40 mg/mL in sequence Regimen A, then Regimen B, then Regimen F, then Regimen C, then Regimen E, then Regimen D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence BCADFE
Description: Oral suspension belumosudil 40 mg/mL in sequence Regimen B, then Regimen C, then Regimen A, then Regimen D, then Regimen F, then Regimen E

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence CDBEAF
Description: Oral suspension belumosudil 40 mg/mL in sequence Regimen C, then Regimen D, then Regimen B, then Regimen E, then Regimen A, then Regimen F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence DECFBA
Description: Oral suspension of belumosudil 40 mg/mL in sequence Regimen D, then Regimen E, then Regimen C, then Regimen F, then Regimen B, then Regimen A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence EFDACB
Description: Oral suspension of belumosudil 40 mg/mL in sequence Regimen E, then Regimen F, then Regimen D, then Regimen A, then Regimen C, then Regimen C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: Belumosudil 40 mg/mL Sequence FAEBDC
Description: Oral suspension of belumosudil 40 mg/mL in sequence Regimen F, then Regimen A, then Regimen E, then Regimen B, then Regimen D, then Regimen C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence GHI
Description: 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence HIG
Description: 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen I (oral suspension; subject fed), then Regimen G (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence IGH
Description: 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen G (tablet), then Regimen H (oral suspension, subject fasted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence IHG
Description: 1 dose of belumosudil 200 mg in sequence Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted), then Regimen G (tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence GIH
Description: 1 dose of belumosudil 200 mg in sequence Regimen G (tablet), then Regimen I (oral suspension; subject fed), then Regimen H (oral suspension; subject fasted)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: Belumosudil 200 mg Sequence HGI
Description: 1 dose of belumosudil 200 mg in sequence Regimen H (oral suspension; subject fasted), then Regimen G (tablet), then Regimen I (oral suspension; subject fed)